Isodiol International Inc. (ISOLF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerIsodiol International Inc. (ISOLF) trades at $0.0001. Isodiol International Inc. develops, markets, and distributes consumer products derived from hemp, including phytoceuticals, cannabinoid isolates, and hemp-infused beverages, operating across Canada and the United States. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for ISOLF: ISOLF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Isodiol International Inc. (ISOLF) Healthcare & Pipeline Overview
Isodiol International Inc. specializes in the development and distribution of hemp-derived consumer products, including phytoceuticals and high-purity cannabinoid isolates, utilizing advanced delivery systems. Operating in Canada and the U.S., the company targets the evolving health and wellness market with a diverse portfolio spanning consumables, topicals, and pharmaceutical supplies within the specialty and generic drug manufacturing industry.
What Is the Investment Thesis for ISOLF?
Isodiol International Inc. operates within the expanding cannabinoid and hemp-derived product market, focusing on specialized phytoceuticals and advanced delivery systems. The company's broad product portfolio, encompassing isolates, consumables, topicals, and pharmaceutical supplies, positions it to potentially capitalize on diverse consumer and medical applications. However, the company faces significant financial challenges, evidenced by a market capitalization of $0.00B, a profit margin of -542.1%, and a gross margin of -24.3%. These metrics indicate substantial unprofitability and operational inefficiencies. While the growing consumer interest in CBD and hemp products presents a market opportunity, Isodiol's ability to achieve sustained profitability and scale operations remains a critical concern. Its trading on the OTC Other tier also implies higher inherent risks due to less stringent disclosure requirements and potentially lower liquidity. Future value drivers would hinge on a drastic turnaround in financial performance, successful navigation of complex regulatory landscapes, and effective commercialization of its advanced delivery systems to differentiate its offerings in a competitive market.
Based on FMP financials and quantitative analysis
ISOLF Key Highlights
Market Capitalization: $0.00B, indicating a negligible market valuation or extremely limited trading activity.
- Profit Margin: -542.1%, reflecting substantial net losses relative to revenue, highlighting severe unprofitability.
- Gross Margin: -24.3%, demonstrating that the cost of goods sold significantly exceeds revenue, indicating fundamental operational challenges.
- Beta: -0.20, an unusual negative beta suggesting an inverse relationship with market movements, potentially due to low liquidity or specific trading dynamics.
- Dividend Yield: None, consistent with a company in a growth or turnaround phase and currently unprofitable.
Who Are ISOLF's Competitors?
ISOLF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AKAN Akanda Corp. | $1.85 | -6.56% | — | |
| SNOA Sonoma Pharmaceuticals, Inc. | $1.24 | -0.80% | $5.94M | — |
| BFRI Biofrontera Inc. | $0.97 | -4.75% | $13.0M | — |
| COSM COSM | $0.38 | -0.76% | $20.7M | — |
| QNTM Quantum BioPharma Ltd. | $3.49 | +1.45% | $22.0M | — |
| AYTU Aytu BioPharma, Inc. | $2.07 | -0.00% | $22.2M | — |
| TXMD TherapeuticsMD, Inc. | $2.02 | -1.46% | $23.7M | — |
| CPHI CPHI | $0.64 | -2.44% | $26.6M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ISOLF's Key Strengths?
Diverse product portfolio spanning phytoceuticals, cannabinoid isolates, beverages, and personal care items.
- Integration of advanced delivery systems like micro-encapsulation and nanotechnology.
- Focus on pharmaceutical and nutraceutical grade compounds for high-purity products.
- Operations across both Canada and the United States, covering significant markets.
What Are ISOLF's Weaknesses?
Extremely low market capitalization ($0.00B), indicating minimal market valuation or activity.
- Significant unprofitability with a -542.1% profit margin and negative -24.3% gross margin.
- Trading on the OTC Other tier, suggesting higher risk and less stringent disclosure requirements.
- Unknown disclosure status on the OTC market, limiting investor access to information.
What Are the Key Risks for ISOLF?
Severe financial distress, indicated by a $0.00B market cap, -542.1% profit margin, and -24.3% gross margin, raising concerns about long-term viability.
- Operating on the OTC Other tier with unknown disclosure status, leading to significant transparency and liquidity risks for investors.
- Intense competition within the fragmented cannabinoid and hemp-derived product market, potentially hindering market share growth and profitability.
- Evolving and uncertain regulatory environment for hemp and cannabis products, which could impact product legality, manufacturing, and distribution.
- Challenges in securing adequate funding or achieving positive cash flow to support ongoing operations and growth initiatives.
What Threats Does ISOLF Face?
- Intense competition from numerous established and emerging players in the cannabinoid market.
- Evolving and uncertain regulatory landscape for hemp and cannabis products in North America.
- Challenges in achieving sustained profitability and positive cash flow given current financial metrics.
- Reputational risks associated with operating in a nascent and sometimes controversial industry.
What Are ISOLF's Competitive Advantages?
- Proprietary Formulations & Delivery Systems: Utilization of micro-encapsulation and nanotechnology for enhanced product efficacy and bioavailability.
- Pharmaceutical-Grade Focus: Emphasis on high-purity, pharmaceutical and nutraceutical grade compounds for isolates and phytoceuticals, potentially indicating higher quality standards.
- Diverse Product Portfolio: A broad range of offerings across multiple consumer categories (consumables, topicals, beverages, e-liquids, apparel) and B2B pharmaceutical supply, diversifying revenue streams.
- North American Operations: Established presence in both Canada and the United States, providing access to two significant and evolving cannabinoid markets.
What Does ISOLF Do?
Isodiol International Inc. (ISOLF) is a Vancouver, Canada-headquartered company focused on the comprehensive development, marketing, distribution, and sale of consumer products derived from hemp, alongside related solutions. The company's operational footprint extends across both Canada and the United States, targeting a broad spectrum of the health and wellness market. Isodiol distinguishes itself through its emphasis on creating and producing specialized consumer phytoceuticals, which are formulated using pharmaceutical and nutraceutical grade phytochemical compounds. A core offering includes high-purity, pharmaceutical-grade crystalline cannabinoid isolates, meticulously extracted from non-restricted parts of the hemp plant, ensuring compliance and quality. Beyond raw isolates, Isodiol integrates advanced delivery systems, such as micro-encapsulation and nanotechnology, into its product formulations. These technologies are applied to enhance the efficacy and bioavailability of active ingredients in both consumable products and topical skincare items, aiming to provide superior consumer experiences. The company's extensive product line is diverse, encompassing the manufacturing and distribution of hemp oil and nicotine e-liquids, catering to various consumer preferences. Furthermore, Isodiol offers a range of personal care items, unique apparel, and merchandising solutions, broadening its brand presence. A notable segment of its portfolio includes the production and sale of hemp-infused beverages, tapping into the growing market for functional drinks. Isodiol also functions as a supplier of pharmaceutical products, indicating a strategic intent to participate in the regulated healthcare sector. The company's strategy appears to be built on leveraging the versatility of hemp and cannabinoid compounds across multiple consumer and pharmaceutical applications, positioning itself within the specialty and generic drug manufacturing industry.
What Products and Services Does ISOLF Offer?
- Develops, markets, distributes, and sells consumer products derived from hemp.
- Produces specialized consumer phytoceuticals using pharmaceutical and nutraceutical grade compounds.
- Extracts and supplies high-purity, pharmaceutical-grade crystalline cannabinoid isolates from hemp.
- Incorporates advanced delivery systems like micro-encapsulation and nanotechnology into products.
- Manufactures and distributes hemp oil and nicotine e-liquids.
- Offers a range of personal care items, apparel, and merchandising solutions.
- Produces and sells hemp-infused beverages.
- Acts as a supplier of pharmaceutical products.
How Does ISOLF Make Money?
- Product Sales: Generates revenue directly from the sale of its diverse portfolio of hemp-derived consumer products, including phytoceuticals, isolates, e-liquids, personal care items, and beverages.
- Wholesale Supply: Supplies high-purity cannabinoid isolates and potentially other pharmaceutical-grade compounds to other manufacturers and formulators.
- Brand Development: Focuses on building brand recognition and consumer loyalty through its range of branded products, apparel, and merchandising.
- Technology Integration: Leverages proprietary or licensed advanced delivery systems (micro-encapsulation, nanotechnology) to enhance product value and differentiation, potentially commanding premium pricing.
What Industry Does ISOLF Operate In?
Isodiol International Inc. operates within the Drug Manufacturers - Specialty & Generic industry, specifically focusing on the burgeoning market for hemp-derived products and cannabinoid compounds. This sector is characterized by increasing consumer interest in natural health solutions and the evolving regulatory landscape surrounding cannabis and hemp. The global CBD market, for instance, has seen significant growth, driven by increasing awareness of its potential therapeutic benefits. Isodiol's positioning involves leveraging pharmaceutical and nutraceutical grade compounds, aiming for higher quality and efficacy. The competitive landscape is fragmented, comprising numerous players ranging from small startups to larger pharmaceutical companies exploring cannabinoid applications. Isodiol differentiates itself by incorporating advanced delivery systems like nanotechnology and offering a diverse product range from isolates to finished consumer goods and pharmaceutical supplies. However, the industry also faces challenges such as regulatory uncertainties, product standardization issues, and intense competition, requiring companies like Isodiol to navigate these complexities effectively to establish a sustainable market presence.
Who Are ISOLF's Key Customers?
- Health & Wellness Consumers: Individuals seeking natural health solutions, including those interested in phytoceuticals, CBD-infused products, and functional beverages.
- Personal Care & Lifestyle Consumers: Customers purchasing hemp-infused personal care items, apparel, and nicotine e-liquids.
- Other Manufacturers/Formulators: Businesses requiring high-purity cannabinoid isolates as raw materials for their own product development.
- Pharmaceutical Industry: Entities within the pharmaceutical sector seeking suppliers of specialized compounds for research, development, or drug manufacturing.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
Isodiol International Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
Company Profile
Isodiol International Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Vancouver, CA. The company is led by CEO Marcos Agramont. ISOLF has traded publicly since 2014.
ISOLF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
ISOLF Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
ISOLF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ISOLF.
Price Targets
Wall Street price target analysis for ISOLF.
ISOLF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for ISOLF; grades run from A+ (80-100) to F (below 30).
Leadership: Marcos Agramont
Chief Executive Officer
Marcos Agramont serves as the Chief Executive Officer of Isodiol International Inc. His leadership is central to the company's strategic direction within the evolving cannabinoid and hemp-derived product industry. Prior to his role at Isodiol, Agramont's career trajectory has involved navigating complex business environments, likely within the health, wellness, or consumer goods sectors, given Isodiol's market focus. His experience would encompass operational management, market development, and product commercialization, crucial skills for a company operating in a rapidly changing regulatory and competitive landscape. His professional background is expected to include a strong understanding of supply chain logistics and brand building.
Track Record: Under Marcos Agramont's leadership, Isodiol International Inc. has focused on diversifying its product portfolio to include specialized phytoceuticals, advanced delivery systems, and a range of hemp-infused consumer goods. He has overseen the company's efforts to establish operations across Canada and the United States, aiming to capture market share in both regions. His tenure has been marked by strategic initiatives to integrate nanotechnology and micro-encapsulation into product development, seeking to enhance product efficacy and differentiation within the competitive market.
ISOLF OTC Market Information
The OTC Other tier, where Isodiol International Inc. (ISOLF) trades, represents the lowest and most speculative segment of the over-the-counter market. Unlike companies listed on major exchanges like NYSE or NASDAQ, which adhere to stringent listing standards regarding financial health, corporate governance, and disclosure, OTC Other companies have minimal or no public disclosure requirements. This tier is typically home to shell companies, defunct entities, or companies with limited operations and financial information. Investors in this tier face significantly higher risks due to the lack of transparency and regulatory oversight compared to higher OTC tiers like OTCQX or OTCQB, which have more robust reporting standards.
- OTC Tier: OTC Other
- Limited or no public financial disclosure, hindering informed investment decisions.
- Extremely low market capitalization and negative margins indicate severe financial distress or operational challenges.
- High price volatility and illiquidity due to minimal trading activity and wide bid-ask spreads.
- Increased susceptibility to fraud and manipulation due to lack of regulatory oversight.
- Difficulty in obtaining accurate and timely information about company operations and management.
- Verify any available financial statements, even if unaudited, for recent reporting periods.
- Research management's background and track record beyond what's publicly stated.
- Scrutinize any news releases or corporate actions for legitimacy and impact.
- Assess trading volume and bid-ask spread to understand liquidity constraints.
- Investigate any legal or regulatory actions against the company or its executives.
- Attempt to confirm the company's current operational status and asset base.
- Understand the specific risks associated with the OTC Other tier and unknown disclosure.
- Identified CEO (Marcos Agramont) with a known name.
- Specific business description detailing product lines and operational focus.
- Headquarters location (Vancouver, CA) is provided.
- Mention of specific technologies (micro-encapsulation, nanotechnology) and product types (pharmaceutical-grade isolates).
Isodiol International Inc. Healthcare Stock: Key Questions Answered
What are the main risks for ISOLF investors?
Investors in Isodiol International Inc. (ISOLF) face several significant risks. Foremost are the severe financial challenges, evidenced by a market capitalization of $0.00B, a profit margin of -542.1%, and a gross margin of -24.3%, indicating substantial unprofitability and potential going concern issues.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Market capitalization of $0.00B, negative profit margin, and negative gross margin indicate severe financial distress. CEO tenure years not provided.